Immunomedics mulls veltuzumab options as Takeda ends deal amid dispute
This article was originally published in Scrip
The US firm Immunomedics has regained all global rights to veltuzumab after Takeda terminated a licensing deal for the anti-CD20 monoclonal antibody.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.